This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
23 May 2011

AstraZeneca's Olaparib Shows Promise in Ovarian Cancer

AstraZeneca said the results may have a positive effect on progression-free survival in women with serous ovarian cancer, and may be a therapeutic option for the aggressive form of cancer.

AstraZeneca has reported positive results from a Phase II study of olaparib, a potential treatment for platinum-sensitive relapsed serous ovarian cancer.

 

Olaparib is an inhibitor of poly-ADP ribose polymerase, an enzyme that plays an important role in repairing DNA damage in cells.

 

The Phase II, randomised, double-blind, multicentre, placebo-controlled study evaluated 265 patients and showed that the drug extended progression-free survival and secondary endpoint of time to progression compared to placebo.

 

AstraZeneca medical science director Jane Robertson said that the results of olaparib may have a positive effect on progression-free survival in women

Related News